Asset Details
Do you wish to reserve the book?
Plasma galectin-3 can be considered as a non-invasive marker to predict the prognosis of ACLF patients with new typing
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Plasma galectin-3 can be considered as a non-invasive marker to predict the prognosis of ACLF patients with new typing
Do you wish to request the book?
Plasma galectin-3 can be considered as a non-invasive marker to predict the prognosis of ACLF patients with new typing
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Plasma galectin-3 can be considered as a non-invasive marker to predict the prognosis of ACLF patients with new typing
2025
Overview
Very recently, we creatively put forward a new classification for ACLF patients, which lays the foundation for the establishment of prognostic model that can accurately predict the prognosis of ACLF patients. Herein, we found: galectin-3 levels were higher in type A ACLF patients compared to those of type B patients; galectin-3 expression was closely correlated with TBil, PTA/INR and MELD; galectin-3 is an independent predictive factor for rapid progression in ACLF, and exhibited superior predictive value for the prognosis of type A ACLF patients than MELD score; and the survival rate was remarkably higher in ACLF patients with lower galectin-3 expression. Collectively, galectin-3 can be considered as a non-invasive biomarker to predict the prognosis of ACLF patients with new typing. Our findings help advance the time window of prognosis prediction for type A and type B ACLF patients from 4 weeks to the baseline, thereby identifying ACLF patients who really need liver transplantation earlier and improving the survival of ACLF patients.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ Acute-on-chronic liver failure
/ Acute-On-Chronic Liver Failure - blood
/ Acute-On-Chronic Liver Failure - classification
/ Acute-On-Chronic Liver Failure - diagnosis
/ Acute-On-Chronic Liver Failure - mortality
/ Adult
/ Female
/ Humanities and Social Sciences
/ Humans
/ Male
/ Science
/ Survival
/ Typing
We currently cannot retrieve any items related to this title. Kindly check back at a later time.